J
James W. Denham
Researcher at University of Newcastle
Publications - 291
Citations - 10842
James W. Denham is an academic researcher from University of Newcastle. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 50, co-authored 280 publications receiving 9910 citations. Previous affiliations of James W. Denham include Mater Health Services & Newcastle University.
Papers
More filters
Journal ArticleDOI
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Bryan Burmeister,B. Mark Smithers,Val Gebski,Lara Fitzgerald,R. John Simes,Peter G. Devitt,Stephen P. Ackland,David C. Gotley,David Joseph,Jeremy Millar,John B. North,Euan Walpole,James W. Denham +12 more
TL;DR: Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone, and further assessment is warranted of the role of cheMoradiotherapy in patients with squamous-cell tumours.
Journal ArticleDOI
The radiotherapeutic injury – a complex ‘wound’
TL;DR: The principles of organised normal tissue responses during and after radiation therapy, the effect of radiation therapy on these responses, as well as some of the mechanisms underlying the development of recognisable injury are reviewed.
Journal ArticleDOI
Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions
Anthony V. D'Amico,James W. Denham,Juanita Crook,Ming-Hui Chen,Samuel Z. Goldhaber,David Lamb,David Joseph,Keen Hun Tai,Shawn Malone,Charles Ludgate,Allison Steigler,Philip W. Kantoff +11 more
TL;DR: The use of AST is associated with earlier onset of fatal MIs in men age 65 years or older who are treated for 6 months compared with men who are not treated with AST.
Journal ArticleDOI
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
James W. Denham,Allison Steigler,David Lamb,David Joseph,Sandra Turner,John W. Matthews,Chris Atkinson,John North,David R. H. Christie,Nigel Spry,Keen Hun Tai,Chris Wynne,Catherine D'Este +12 more
TL;DR: 6 months of neoadjuvant androgen deprivation combined radiotherapy is an effective treatment option for locally advanced prostate cancer, particularly in men without nodal metastases or pre-existing metabolic comorbidities.
Journal ArticleDOI
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
James W. Denham,Allison Steigler,David Lamb,David Joseph,Hedy Mameghan,Sandra Turner,John W. Matthews,Ian Franklin,Chris Atkinson,John B. North,Michael Poulsen,David R. H. Christie,Nigel Spry,Keen Hun Tai,Chris Wynne,Gillian M. Duchesne,Olga Kovacev,Catherine D'Este +17 more
TL;DR: 6 months' androgen deprivation given before and during radiotherapy improves the outlook of patients with locally advanced prostate cancer and is needed to estimate precisely the size of survival benefits.